BCPC · Insider Trading
Balchem Corporation
Every open-market purchase and sale reported by BCPC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-13 | David B Fischer | Director | A | +870 | — |
| 2026-02-13 | Kathleen B Fish | Director | A | +870 | — |
| 2026-02-13 | Daniel E Knutson | Director | A | +870 | — |
| 2026-02-13 | Olivier Rigaud | Director | A | +870 | — |
| 2026-02-13 | Monica Vicente | Director | A | +870 | — |
| 2026-02-13 | George Graham | SVP and Chief R&D Officer | A | +700 | — |
| 2026-02-13 | Frederic Boned | SVP/GM, Human Nutri. & Health | MIXED | +3,763 | −$241.69K |
| 2026-02-13 | Martin Luther Reid | SVP Chief Supply Chain Officer | MIXED | +2,098 | −$214.46K |
| 2026-02-13 | Michael Brent Tignor | SVP & Chief HR Officer | MIXED | +1,973 | −$206.36K |
| 2026-02-13 | Matthew David Wineinger | Director | A | +870 | — |
| 2026-02-13 | Carl Martin Bengtsson | EVP & Chief Financial Officer | MIXED | +5,610 | −$485.29K |
| 2026-02-13 | William A. Backus | VP & Chief Accounting Officer | MIXED | +1,219 | −$166.98K |
| 2026-02-13 | Hatsuki Miyata | EVP, CLO, & Secretary | MIXED | +2,899 | −$188.83K |
| 2026-02-13 | Theodore L Harris | Chairman, President & CEO | MIXED | +15,439 | −$1.82M |
| 2026-02-13 | Job Leonard van Gunsteren | SVP and GM, Specialty Products | MIXED | +961 | −$145.38K |
| 2026-02-10 | William A. Backus | VP & Chief Accounting Officer | F | −322 | −$55.76K |
| 2026-02-10 | Job Leonard van Gunsteren | SVP and GM, Specialty Products | F | −258 | −$44.68K |
| 2026-02-10 | Hatsuki Miyata | EVP, CLO, & Secretary | F | −343 | −$59.39K |
| 2026-02-10 | Theodore L Harris | Chairman, President & CEO | F | −3,225 | −$558.44K |
| 2026-02-10 | Martin Luther Reid | SVP Chief Supply Chain Officer | F | −416 | −$72.03K |
| 2026-02-10 | William A. Backus | VP & Chief Accounting Officer | F | −383 | −$64.05K |
| 2026-02-10 | Frederic Boned | SVP/GM, Human Nutri. & Health | F | −430 | −$74.46K |
| 2026-02-10 | Michael Brent Tignor | SVP & Chief HR Officer | F | −373 | −$64.59K |
| 2026-02-10 | Carl Martin Bengtsson | EVP & Chief Financial Officer | F | −863 | −$149.44K |
| 2025-12-05 | David B Fischer | Director | MIXED | −2,000 | −$759.41K |
| 2025-12-05 | Job Leonard van Gunsteren | SVP and GM, Specialty Products | MIXED | — | −$554.62K |
| 2025-11-13 | Martin Luther Reid | SVP Chief Supply Chain Officer | Sell | −1,200 | −$185.33K |
| 2025-11-03 | Frederic Boned | SVP/GM, Human Nutri. & Health | F | −1,085 | −$166.43K |
| 2025-10-22 | George Graham | SVP and Chief R&D Officer | A | +2,500 | — |
| 2025-07-28 | Hatsuki Miyata | EVP, CLO, & Secretary | F | −483 | −$71.88K |
| 2025-04-11 | David B Fischer | Director | A | +980 | — |
| 2025-04-11 | Daniel E Knutson | Director | A | +980 | — |
| 2025-04-11 | Job Leonard van Gunsteren | SVP and GM, Specialty Products | MIXED | +1,164 | −$157.27K |
| 2025-04-11 | Hatsuki Miyata | EVP, CLO, & Secretary | A | +1,840 | — |
| 2025-04-11 | Frederic Boned | SVP/GM, Human Nutri. & Health | A | +1,580 | — |
| 2025-04-11 | Monica Vicente | Director | A | +980 | — |
| 2025-04-11 | Theodore L Harris | Chairman, President & CEO | MIXED | +17,522 | −$1.87M |
| 2025-04-11 | Matthew David Wineinger | Director | A | +980 | — |
| 2025-04-11 | Olivier Rigaud | Director | A | +980 | — |
| 2025-04-11 | Martin Luther Reid | SVP Chief Supply Chain Officer | MIXED | +2,830 | −$172.77K |
| 2025-04-11 | Carl Martin Bengtsson | EVP & Chief Financial Officer | MIXED | +5,011 | −$453.69K |
| 2025-04-11 | Kathleen B Fish | Director | A | +980 | — |
| 2025-04-11 | William A. Backus | VP & Chief Accounting Officer | MIXED | +1,544 | −$175.05K |
| 2025-04-11 | Michael Brent Tignor | SVP & Chief HR Officer | MIXED | +2,341 | −$188.59K |
| 2025-02-14 | Matthew David Wineinger | Director | A | +980 | — |
| 2025-02-14 | Daniel E Knutson | Director | A | +980 | — |
| 2025-02-14 | David B Fischer | Director | A | +980 | — |
| 2025-02-14 | Kathleen B Fish | Director | A | +980 | — |
| 2025-02-14 | Monica Vicente | Director | A | +980 | — |
| 2025-02-14 | William A. Backus | VP & Chief Accounting Officer | MIXED | +1,544 | −$175.05K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Theodore L Harris | Chairman, President & CEO | 92,395 | $15.77M |
| Carl Martin Bengtsson | EVP & Chief Financial Officer | 29,314 | $5.00M |
| Michael Brent Tignor | SVP & Chief HR Officer | 12,344 | $2.11M |
| Job Leonard van Gunsteren | SVP and GM, Specialty Products | 10,963 | $1.87M |
| David B Fischer | Director | 8,859 | $1.51M |
| Frederic Boned | SVP/GM, Human Nutri. & Health | 8,526 | $1.46M |
| Martin Luther Reid | SVP Chief Supply Chain Officer | 8,457 | $1.44M |
| Hatsuki Miyata | EVP, CLO, & Secretary | 8,043 | $1.37M |
| Matthew David Wineinger | Director | 8,012 | $1.37M |
| William A. Backus | VP & Chief Accounting Officer | 7,089 | $1.21M |
| Daniel E Knutson | Director | 6,899 | $1.18M |
| Michael Robert Sestrick | SVP & Chief Technology Officer | 5,610 | $957.80K |
| Kathleen B Fish | Director | 3,429 | $585.43K |
| George Graham | SVP and Chief R&D Officer | 3,220 | $549.75K |
| Monica Vicente | Director | 2,390 | $408.04K |
| Olivier Rigaud | Director | 2,390 | $408.04K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BCPC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.